Cargando…
Ocular side effects of biological agents in oncology: what should the clinician be aware of?
During the last 20 years, biologicals have become increasingly relevant in oncologic therapy. Depending on the medication used, there are different profiles of ocular side effects. Although these can be present in up to 70% of patients, they are generally underreported in the literature. Therefore,...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878959/ https://www.ncbi.nlm.nih.gov/pubmed/24391443 http://dx.doi.org/10.2147/OTT.S54606 |
_version_ | 1782297894758383616 |
---|---|
author | Hager, Tobias Seitz, B |
author_facet | Hager, Tobias Seitz, B |
author_sort | Hager, Tobias |
collection | PubMed |
description | During the last 20 years, biologicals have become increasingly relevant in oncologic therapy. Depending on the medication used, there are different profiles of ocular side effects. Although these can be present in up to 70% of patients, they are generally underreported in the literature. Therefore, the pathophysiological details of their development are often poorly understood. Herein we attempt to identify groups of biologicals to which a specific side effect profile can be assigned. We also tried to capture all relevant side effects and therefore conducted several database investigation including Medline, Cochrane library, and the drugs section of the US Food and Drug Administration (FDA), using the following search strings: “name of biological agent (both generic and commercial names)” AND “eye” OR “ocular”. If we found a side effect that has been associated with a drug, we researched Medline using the following search string: “name of biological agent” (both generic and commercial names) AND “term for the specific side effect”. Due to the wealth of material we report only the drugs that are approved by the FDA. |
format | Online Article Text |
id | pubmed-3878959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38789592014-01-03 Ocular side effects of biological agents in oncology: what should the clinician be aware of? Hager, Tobias Seitz, B Onco Targets Ther Review During the last 20 years, biologicals have become increasingly relevant in oncologic therapy. Depending on the medication used, there are different profiles of ocular side effects. Although these can be present in up to 70% of patients, they are generally underreported in the literature. Therefore, the pathophysiological details of their development are often poorly understood. Herein we attempt to identify groups of biologicals to which a specific side effect profile can be assigned. We also tried to capture all relevant side effects and therefore conducted several database investigation including Medline, Cochrane library, and the drugs section of the US Food and Drug Administration (FDA), using the following search strings: “name of biological agent (both generic and commercial names)” AND “eye” OR “ocular”. If we found a side effect that has been associated with a drug, we researched Medline using the following search string: “name of biological agent” (both generic and commercial names) AND “term for the specific side effect”. Due to the wealth of material we report only the drugs that are approved by the FDA. Dove Medical Press 2013-12-24 /pmc/articles/PMC3878959/ /pubmed/24391443 http://dx.doi.org/10.2147/OTT.S54606 Text en © 2014 Hager and Seitz. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Hager, Tobias Seitz, B Ocular side effects of biological agents in oncology: what should the clinician be aware of? |
title | Ocular side effects of biological agents in oncology: what should the clinician be aware of? |
title_full | Ocular side effects of biological agents in oncology: what should the clinician be aware of? |
title_fullStr | Ocular side effects of biological agents in oncology: what should the clinician be aware of? |
title_full_unstemmed | Ocular side effects of biological agents in oncology: what should the clinician be aware of? |
title_short | Ocular side effects of biological agents in oncology: what should the clinician be aware of? |
title_sort | ocular side effects of biological agents in oncology: what should the clinician be aware of? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878959/ https://www.ncbi.nlm.nih.gov/pubmed/24391443 http://dx.doi.org/10.2147/OTT.S54606 |
work_keys_str_mv | AT hagertobias ocularsideeffectsofbiologicalagentsinoncologywhatshouldtheclinicianbeawareof AT seitzb ocularsideeffectsofbiologicalagentsinoncologywhatshouldtheclinicianbeawareof |